<DOC>
	<DOCNO>NCT00137917</DOCNO>
	<brief_summary>The purpose study evaluate immunogenicity , safety reactogenicity 3 dos meningococcal serogroup B vaccine give , use either 0-2-4 month 0-1-6 month schedule , healthy adolescent age 12-18 year ; control group receive 2 dos Havrix™ ( 0-6 month ) Meningitec™ ( month 1 ) .</brief_summary>
	<brief_title>Immunogenicity &amp; Safety Study Meningococcal Serogroup B Vaccine Given 3 Dose Schedule Healthy Adolescents Aged 12-18 Yrs</brief_title>
	<detailed_description>The study open ; however , vaccine give study group 0-1-6 month control group administer observer-blind manner . 3 blood sampling antibody test : vaccination one month second third vaccine dos .</detailed_description>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy male female , include , 12 18 year age time first vaccination . Female subject must nonchildbearing potential . Previous vaccination history meningococcal B C , hepatitis A disease exposure meningococcal B disease within last year . Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection . Family history congenital hereditary immunodeficiency . History neurologic disorder seizure .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Prophylaxis meningococcal serogroup B disease</keyword>
</DOC>